首页> 外文期刊>Behavioral and Brain Functions >Association between Ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients
【24h】

Association between Ghrelin gene (GHRL) polymorphisms and clinical response to atypical antipsychotic drugs in Han Chinese schizophrenia patients

机译:Ghrelin基因(GHRL)多态性与汉族精神分裂症患者对非典型抗精神病药的临床反应之间的关联

获取原文
       

摘要

Background Ghrelin (GHRL) is a pivotal peptide regulator of food intake, energy balance, and body mass. Weight gain (WG) is a common side effect of the atypical antipsychotics (AAPs) used to treat schizophrenia (SZ). Ghrelin polymorphisms have been associated with pathogenic variations in plasma lipid concentrations, blood pressure, plasma glucose, and body mass index (BMI). However, it is unclear whether GHRL polymorphisms are associated with WG due to AAPs. Furthermore, there is no evidence of an association between GHRL polymorphisms and SZ or the therapeutic response to AAPs. We explored these potential associations by genotyping GHRL alleles in SZ patients and controls. We also examined the relation between these SNPs and changes in metabolic indices during AAP treatment in SZ subgroups distinguished by high or low therapeutic response. Methods Four SNPs (Leu72Met, -501A/C, -604 G/A, and -1062 G > C) were genotyped in 634 schizophrenia patients and 606 control subjects. Results There were no significant differences in allele frequencies, genotype distributions, or the distributions of two SNP haplotypes between SZ patients and healthy controls (P > 0.05). There was also no significant difference in symptom reduction between genotypes after 8 weeks of AAP treatment as measured by positive and negative symptom scale scores (PANSS). However, the -604 G/A polymorphism was associated with a greater BMI increase in response to AAP administration in both APP responders and non-responders as distinguished by PANSS score reduction (P P Conclusions These four GHRL gene SNPs were not associated with SZ in this Chinese Han population. The -604 G/A polymorphism was associated with significant BW and BMI increases during AAP treatment. Patients exhibiting higher WG showed greater improvements in positive and negative symptoms than patients exhibiting lower weight gain or weight loss.
机译:背景Ghrelin(GHRL)是食物摄入,能量平衡和体重的关键肽调节剂。体重增加(WG)是用于治疗精神分裂症(SZ)的非典型抗精神病药(AAP)的常见副作用。 Ghrelin多态性与血浆脂质浓度,血压,血浆葡萄糖和体重指数(BMI)的致病性变化有关。然而,尚不清楚由于AAP,GHRL多态性是否与WG相关。此外,没有证据表明GHRL多态性与SZ或对AAP的治疗反应相关。我们通过对SZ患者和对照中GHRL等位基因进行基因分型,探索了这些潜在的关联。我们还检查了以高或低治疗反应为特征的SZ亚组在AAP治疗期间这些SNP与代谢指标变化之间的关系。方法对634例精神分裂症患者和606例对照者的4个SNP(Leu72Met,-501A / C,-604 G / A和-1062 G> C)进行基因分型。结果SZ患者与健康对照组之间的等位基因频率,基因型分布或两种SNP单倍型的分布无显着差异(P> 0.05)。 AAP治疗8周后,基因型之间的症状减轻也没有显着差异,通过阳性和阴性症状量表评分(PANSS)进行测量。但是,-604 G / A多态性与APP应答者和非应答者对AAP给药的BMI升高相关,这与PANSS得分降低明显不同(PP结论这四个GHRL基因SNP与SZ无关)。中国汉族人群-604 G / A基因多态性与AAP治疗期间显着的BW和BMI升高有关,WG较高的患者在正负症状方面的改善比体重增加或体重减轻较低的患者更大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号